Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 9;171:104598. doi: 10.1016/j.antiviral.2019.104598

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — STAT1 and S6 Phosphorylation States After Antiviral Drug Stimulation. A. pSTAT1 signaling was identified as a marker for IFN rich treatment, but not for RIB rich treatment. B. pSTAT1 is an instant, long-lasting marker for IFN treatment. Activation of pSTAT1 was available as early as 0.5 h after drug stimulations and continued for up to 16 h after IFN drug treatments. C. pS6 signaling was identified as a marker for RIB rich treatment, but not for IFN rich treatment. D. pS6 signaling was not an instant marker but a later-period marker for RIB treatment, as pS6 level did not change until 8 h after drug treatments. E. Quantification of pSTAT1 and pS6 signaling in samples treated with Optimal_A and Optimal_B indicates pSTAT1 signaling is Optimal_A specific and pS6 is optimal_B specific. Unit for drugs is ng/ml. As a reminder: high dose IFNs and ACV (Optimal_A and Optimal_AA), high dose RIB and ACV (Optimal_B), low dose IFNs and ACV (Subopt_A), and low dose IFNs and RIB (Subopt_B). For Part E, data plotted is mean ± standard deviation. All experimental data shown is representative data from three independent experiments.